Stockreport

Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma

IMMUNE DESIGN CORP COMMON STOCK  (IMDZ) 
Last immune design corp common stock earnings: 11/6 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.immunedesign.com/investor-relations
PDF           -- 1st global Phase 3 trial focused on synovial sarcoma patients [Read more]